0001140361-17-002340.txt : 20170119
0001140361-17-002340.hdr.sgml : 20170119
20170119211549
ACCESSION NUMBER: 0001140361-17-002340
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170117
FILED AS OF DATE: 20170119
DATE AS OF CHANGE: 20170119
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Emergent BioSolutions Inc.
CENTRAL INDEX KEY: 0001367644
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 141902018
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
BUSINESS PHONE: 240-631-3200
MAIL ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Havey Adam
CENTRAL INDEX KEY: 0001514588
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33137
FILM NUMBER: 17537411
MAIL ADDRESS:
STREET 1: 2273 RESEARCH BLVD SUITE 400
CITY: ROCKVILLE
STATE: MD
ZIP: 20853
4
1
doc1.xml
FORM 4
X0306
4
2017-01-17
0
0001367644
Emergent BioSolutions Inc.
EBS
0001514588
Havey Adam
400 PROFESSIONAL DR, SUITE 400
GAITHERSBURG
MD
20879
0
1
0
0
EVP, Biodefense Divison
Common Stock
2016-08-01
4
J
0
452
0
A
41424
D
Common Stock
2016-08-01
4
J
0
599
0
A
42023
D
Common Stock
2016-08-01
4
J
0
748
0
A
42771
D
Common Stock
2017-01-17
4
S
0
8438
29.7465
D
34333
D
Stock Option (Right to buy)
22.03
2016-08-01
4
J
0
577
0
A
2018-03-14
Common Stock
577
6573
D
Stock Option (Right to buy)
22.03
2016-08-01
4
J
0
1386
0
A
2018-03-14
Common Stock
1386
15770
D
Stock Option (Right to buy)
25.62
2016-08-01
4
J
0
2709
0
A
2021-03-10
Common Stock
2709
30828
D
Stock Option (Right to buy)
26.45
2016-08-01
4
J
0
1794
0
A
2022-03-09
Common Stock
1794
20414
D
Stock Option (Right to buy)
30.86
2016-08-01
4
J
0
1495
0
A
2023-02-28
Common Stock
1495
17009
D
In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as
a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017.
In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as
a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017 and March 2018.
In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as
a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017, March 2018 and March 2019.
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.48 to $30.15, inclusive.
Consists of an option granted on 03/15/2011 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.
The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.
Consists of an option granted on 03/11/2014 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.
Consists of an option granted on 03/10/2015 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.
Consists of an option granted on 03/01/2016 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.
/s/ Eric Burt, Attorney-in-fact
2017-01-19